Is Coya Therapeutics, Inc. (NASDAQ:COYA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Coya Therapeutics, Inc. at current levels.
A $112M biotech with a Phase 2 ALS combo, a Dr. Reddy's partnership, and readouts that could re-rate the whole Treg category.
Where COYA is headed
By mid-2027, Coya is either a $600M-$1B neuroinflammation platform company with the first credible disease-modifying combination in ALS, or it's a $40M shell trading below cash. There is very little middle ground here, and pretending otherwise would be dishonest. That binary is the entire investment case.
Read the full Compass Direction on COYA
The complete destination call, the overlooked angle, milestones, and bull, base, and bear price scenarios (around $4.99).
See the full COYA analysisGet calls like this, free
Join the Alexandria e-letter for forward-looking verdicts, earnings intelligence, and the contrarian reads the crowd misses. Twice a week, no noise.
Free forever. Unsubscribe anytime. We never share your email.
Frequently asked questions
Is Coya Therapeutics, Inc. (NASDAQ:COYA) a buy in 2026?
Yes, on balance. The Compass leans toward accumulating Coya Therapeutics, Inc. at current levels. A $112M biotech with a Phase 2 ALS combo, a Dr. Reddy's partnership, and readouts that could re-rate the whole Treg category.
What is COYA's Compass Score?
Coya Therapeutics, Inc. scores 74/100 on Alexandria's Compass, placing it in the "Favorable" tier. Scores blend eight factors and update weekly.
What is the price target for COYA?
Alexandria's full Compass Direction includes bull, base, and bear price scenarios with the valuation math behind each. Read the full breakdown on the COYA page.
Compass verdicts are AI-generated, forward-looking editorial research from publicly available data, not investment advice or a recommendation regarding any security. Scores and verdicts update as the data changes.